Home | Sitemap | Search | Contact A- A A+
   
 
    Public Member Support us  
 

IBCSG 16-98 / BIG 2-97 

Exemestane vs. tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer who have received adjuvant tamoxifen for 2-3 years

DESIGN

Design Trial 16-98

Results & Publications


Presentations


Posters


Publications

Study Chairs
Dr. Hervé Bonnefoi - Genève, Switzerland
Prof. Alan Coates - Centennial Park, Australia

Trial Coordinators
Holly Shaw

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 836 6097
Email: ibcsg16@fstrf.org

Date of Activation
May 1998

Date of Closure
August 31, 2001

Targeted Accrual
4400 patients

Final Accrual
4742 patients


Results Publications Results & Publications


News

18.12.2014:
New publications are available 

11.12.2014:
San Antonio Breast Cancer Symposium 2014: IBCSG Presents SOFT Results.

10.12.2014:
IBCSG and Merck Announce Opening of International PANACEA Study of Patients with HER2+ Breast

All News

 
  Print